[Tamoxifen induced thromboembolic events in breast cancer. Some possible mechanisms].
Tamoxifen is an antagonist of the oestrogen receptor, used in the treatment of breast cancer. It is known to reduce osteoporotic bone fractures, but it increases the risk of endometrial tumors and venous thromboembolic events (VTEs). VTEs increased significantly during tamoxifen therapy within 3 months of major surgery, immobilization or fracture. Their incidence is associated with patients' risk factors, tumor and tissue induced procoagulation. The mechanisms are still not well known. There is a need for a better understanding in order to develope a prophylactic and therapeutic strategy.